Polyomavirus‐driven Merkel cell carcinoma: Prospects for therapeutic vaccine development
- 27 March 2020
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 59 (7) , 807-821
Abstract
Great strides have been made in cancer immunotherapy including the breakthrough successes of anti‐PD‐(L)1 checkpoint inhibitors. In Merkel cell carcinoma (MCC), a rare and aggressive skin cancer, PD‐(L)1 blockade is highly effective. Yet, ~50% of patients either do not respond to therapy or develop PD‐(L)1 refractory disease and, thus, do not experience long‐term benefit. For these patients, additional or combination therapies are needed to augment immune responses that target and eliminate cancer cells. Therapeutic vaccines targeting tumor‐associated antigens, mutated self‐antigens, or immunogenic viral oncoproteins are currently being developed to augment T‐cell responses. Approximately 80% of MCC cases in the United States are driven by the ongoing expression of viral T‐antigen (T‐Ag) oncoproteins from genomically integrated Merkel cell polyomavirus (MCPyV). Since T‐Ag elicits specific B‐ and T‐cell immune responses in most persons with virus‐positive MCC (VP‐MCC), and ongoing T‐Ag expression is required to drive VP‐MCC cell proliferation, therapeutic vaccination with T‐Ag is a rational potential component of immunotherapy. Failure of the endogenous T‐cell response to clear VP‐MCC (allowing clinically evident tumors to arise) implies that therapeutic vaccination will need to be potent anśd synergize with other mechanisms to enhance T‐cell activity against tumor cells. Here, we review the relevant underlying biology of VP‐MCC, potentially applicable therapeutic vaccine platforms, and antigen delivery formats. We also describe early successes in the field of therapeutic cancer vaccines and address several clinical scenarios in which VP‐MCC patients could potentially benefit from a therapeutic vaccine.Keywords
Funding Information
- National Institutes of Health (NIH‐P01‐CA225517, NIH‐T32‐CA080416)
This publication has 130 references indexed in Scilit:
- A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesionsCancer Immunology, Immunotherapy, 2012
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patientsProceedings of the National Academy of Sciences, 2012
- Merkel Cell Polyomavirus Large T Antigen Disrupts Lysosome Clustering by Translocating Human Vam6p from the Cytoplasm to the NucleusJournal of Biological Chemistry, 2011
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated PatientsMolecular Therapy, 2011
- Merkel Cell Polyomavirus and Two Previously Unknown Polyomaviruses Are Chronically Shed from Human SkinCell Host & Microbe, 2010
- Progress and prospects: immune responses to viral vectorsGene Therapy, 2009
- Association of Merkel Cell Polyomavirus–Specific Antibodies With Merkel Cell CarcinomaJNCI: Journal of the National Cancer Institute, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirusProceedings of the National Academy of Sciences, 2008
- The known unknowns of antigen processing and presentationNature Reviews Immunology, 2008